-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下：我们将GPI的12个月目标价下调10美元至375美元，基于2027年7.9倍的市盈率，略高于GPI过去10年的平均预期市盈率7.7倍。我们将2026年调整后每股收益预期从44.40美元下调至41.50美元，2027年调整后每股收益预期从48.40美元下调至47.70美元。鉴于GPI近期业绩异常疲软，我们维持对GPI股票的“持有”评级。在发布财报之前，GPI过去八年的季度盈利超过预期90%以上，但第一季度销售额令人失望，导致盈利大幅低于预期，因此我们维持“持有”评级。不过，值得欣慰的是，GPI英国业务的业绩有所改善。从积极的方面来看，GPI继续积极通过分红和股票回购向股东返还现金，第一季度回购了1.7%的流通股。汽车经销商的基本面依然严峻，本季度GPI的盈利连续第三个季度未达预期，而该公司此前曾拥有汽车零售业最佳的盈利记录之一。
Related Articles
Research
Research Alert: CFRA Maintains Hold Opinion On Shares Of American Water Works Company, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target by $1 to $139, 21.2x our 2027 EPS estimate, a discount to AWK's five-year forward average of 25.1x. We keep our 2026 EPS view at $6.09 and lift 2027 EPS by $0.08 to $6.58. The Q1 EPS miss (-7.4%) is the latest in a series of misses, with seven in the last nine quarters coming in below expectations at an average of -3.1%. Our Hold opinion reflects our moderately balanced view of risks and rewards, particularly around the WTRG merger, though regulatory approval in Kentucky provides some relief to transaction uncertainty. We think higher for longer interest rates will pressure valuations. In the FOMC's most recent meeting, three regional presidents backed the hold on rates but rejected the statement's easing bias, which we interpret as a signal that the Fed's next move may not be a rate cut. We think the acceleration of closing expectations (June 30, 2026 vs. August 2026) for the Nexus Water Group Systems will boost 2026 sales, as we now anticipate 7% Y/Y growth.
$AWK
Research
Research Alert: CFRA Maintains Buy Rating On Shares Of Labcorp Holdings Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $300 from $325, 16.6x our 2026 EPS estimate, a premium to LH's three-year historical forward average of 15.3x, supported by our favorable view for health care services, including healthy lab testing volume growth within an environment of high medical utilization, as well as attractive growth prospects given new therapies and aging demographics, in our opinion. We raise our 2026 EPS estimate to $18.03 from $17.90 and raise our 2027 estimate to $19.32 from $19.15. Q1 2026 acquisitions were $202 million, including operations from Crouse Health's Laboratory Alliance of Central New York, while management expressed confidence in the upcoming deal pipeline during the Q1 earnings conference call. Acquisitions totaled $582 million during 2025. LH anticipates a 30 bps headwind for diagnostics volumes in 2026 due to the recent expiration of ACA enhanced premium tax credits, which we expect to cause a meaningful drop in ACA exchange insurance coverage.
$LH
Research
Research Alert: CFRA Maintains Buy Rating On Shares Of Cardinal Health Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $225 from $260, 19.3x our FY 27 EPS estimate (up $0.24 to $11.66; FY 26 estimate up to $10.75 from $10.28), a premium to CAH's one- and three-year historical forward averages of 17.2x and 14.7x, respectively, to reflect our favorable outlook for pharmaceutical distributors.
$CAH